Osmotica Pharmaceutical

51 articles about Osmotica Pharmaceutical

• UPDATE – Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance

  1/19/2022

  Osmotica Pharmaceuticals plc, a specialty pharmaceutical company, announced that the Company has changed its name to RVL Pharmaceuticals plc .

• Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance

  1/19/2022

  Osmotica Pharmaceuticals plc announced today that the Company has changed its name to RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL”).

• RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022

  1/18/2022

  Osmotica Pharmaceuticals plc announced today that Brian Markison, Chief Executive Officer and James “JD” Schaub, Chief Operating Officer, will host a video webcast to discuss recent UPNEEQ® trends, pending expansion into the medical aesthetics market and other general business updates.

• Osmotica Pharmaceuticals plc to Present at Jefferies London Virtual Healthcare Conference 2021

  11/15/2021

  Osmotica Pharmaceuticals plc announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present at the Jefferies London Virtual Healthcare Conference 2021 as follows: Date: Thursday, November 18, 2021

• Osmotica Pharmaceuticals plc Reports Third Quarter 2021 Results and Provides Business Update

  11/15/2021

  Osmotica Pharmaceuticals plc, a specialty pharmaceutical company, announced business highlights and financial results for the three months ended September 30, 2021.

• Osmotica Pharmaceuticals plc Announces Closing of $35 Million Underwritten Public Offering

  10/13/2021

  Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that on October 12, 2021, it closed its previously announced underwritten public offering of 14,000,000 ordinary shares of the Company and warrants to purchase up to 14,000,000 ordinary shares, at a public offering price of $2.50 per share and accompanying warrant.

• Osmotica Pharmaceuticals plc Announces Debt Financing from Athyrium Capital Management of up to $100 Million

  10/7/2021

  Osmotica Pharmaceuticals plc, a specialty pharmaceutical company, announced that it has entered into a note purchase agreement for up to $100 million of senior secured notes with funds managed by Athyrium Capital Management.

• Osmotica Pharmaceuticals Announces Pricing of $35 Million Underwritten Public Offering - Oct 07, 2021

  10/7/2021

  Osmotica Pharmaceuticals plc, a specialty pharmaceutical company, announced the pricing of its previously announced underwritten public offering of 14,000,000 ordinary shares of the Company and warrants to purchase up to 14,000,000 ordinary shares at a public offering price of $2.50 per share and accompanying warrant.

• Osmotica Pharmaceuticals plc to Present at Cantor Virtual Global Healthcare Conference 2021

  9/22/2021

  Osmotica Pharmaceuticals plc announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present at the Cantor Virtual Global Healthcare Conference 2021 as follows: Date: Monday, September 27, 2021 Time: 10:00 a.m. Eastern Time

• Osmotica Pharmaceuticals plc Closes Sale of Legacy Business to Alora Pharmaceuticals, LLC

  8/30/2021

  Osmotica Pharmaceuticals plc, a specialty pharmaceutical company, announced that it has closed the previously announced sale of its legacy business, including certain of the Company’s US subsidiaries dedicated to the legacy business and its Marietta, Georgia, manufacturing facility, to Alora Pharmaceuticals, LLC, effective August 27, 2021.

• Osmotica Subsidiary RVL Pharmaceuticals, Focused on Eye Care and Ocular Aesthetics, Strengthens and Expands Leadership Team

  6/30/2021

  Osmotica Pharmaceuticals plc today announced that J. Aaron Green will join the leadership team of RVL Pharmaceuticals, Inc.

• Osmotica Pharmaceuticals plc Announces Conclusion of Strategic Process with Agreement for the Sale of Legacy Business to Alora Pharmaceuticals, LLC

  6/25/2021

  Osmotica Pharmaceuticals, plc, a fully integrated biopharmaceutical company, announced that it has entered into a definitive Purchase and Sale Agreement with Alora Pharmaceuticals, LLC pursuant to which Alora will acquire Osmotica’s portfolio of legacy products and its Marietta, Georgia manufacturing facility, for up to $170 million.

• Osmotica Pharmaceuticals plc to Provide Fourth Quarter and Full Year 2020 Business and Financial Update on March 30, 2021

  3/24/2021

  Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2020 fourth quarter and full year financial results on Tuesday, March 30, 2021, after the close of the U.S. financial markets.

• Osmotica to Present at 10th Annual SVB Leerink Global Healthcare Conference

  2/18/2021

  Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at the 10th Annual SVB Leerink Global Healthcare Conference as follows: Date: Wednesday, February 24, 2021 Time: 9:20 a.m. Eastern Time Webcast: https://wsw.com/webcast/svbleerink47/osmt/269

• Adamas Completes Acquisition of OSMOLEX ER®Royalty-Backed Loan Agreement Amendment Effective with OSMOLEX ER Acquisition

  1/5/2021

  Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the closing of the settlement of patent litigation with Osmotica Pharmaceutical US LLC, a subsidiary of Osmotica Pharmaceuticals plc and completes the acquisition of the global rights to OSMOLEX ER®. As previously disclosed, the amended Royalty-

• Osmotica Pharmaceuticals plc Announces Agreement to Settle Patent Litigation with Adamas

  12/2/2020

  Adamas to acquire global rights to OSMOLEX ER ® for $7.5 million Company to focus on maximizing commercial opportunity for Upnee q™ BRIDGEWATER, N.J., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that its subsidiary Osmotica Pharmaceutical US LLC has entered into an agreement to settle its ongoing patent litigation with Adamas Pharmaceuticals, Inc. r

• Osmotica Pharmaceuticals plc to Present at 2020 Jefferies Virtual London Healthcare Conference

  11/12/2020

  Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at the 2020 Jefferies Virtual London Healthcare Conference as follows: Date: Wednesday, November 18, 2020 Time: 11:25 a.m. Eastern Time Webcast: https://wsw.com/webcast/jeff141/osmt/1873875

• Osmotica Pharmaceuticals plc Reports Third Quarter 2020 Results and Provides Business Updates

  11/10/2020

  Third quarter 2020 total revenue of $57.2 million Received U.S Food and Drug Administration (“FDA”) approval for Upneeq ™ (oxymetazoline hydrochloride ophthalmic solution), 0.1% for acquired blepharoptosis (ptosis or droopy eyelid) in adults Launched Upneeq from new operating subsidiary, RVL Pharmaceuticals, enabling broad access for providers and patients Early experience program,

• Osmotica to Present at 2020 Wells Fargo Virtual Healthcare Conference

  9/2/2020

  - Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James “JD” Schaub, Chief Operating Officer, will present at the 2020 Wells Fargo Virtual Healthcare Conference as follows: Date: Thursday, September 10, 2020 Time: 11:20 a.m. Eastern Time Webcast: https://metroconnections.zoom.us/webinar/regis

• Osmotica Pharmaceuticals plc to Provide Second Quarter 2020 Business and Financial Update and Presentation on Upneeq™ on August 11, 2020

  8/7/2020

  Company to discuss launch plans for Upneeq and will be joined by Dr. Derek Cunningham, OD, FAAO